Fulcrum Therapeutics (FULC) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

FULC Stock Forecast

Fulcrum Therapeutics stock forecast is as follows: an average price target of $3.25 (represents a -25.29% downside from FULC’s last price of $4.35) and a rating consensus of 'Buy', based on 15 wall street analysts offering a 1-year stock forecast.

FULC Price Target

The average price target for Fulcrum Therapeutics (FULC) is $3.25 based on 1-year price targets from 15 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $2.00. This represents a potential -25.29% downside from FULC's last price of $4.35.

FULC Analyst Ratings

Buy

According to 15 Wall Street analysts, Fulcrum Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FULC stock is 0 'Strong Buy' (0.00%), 7 'Buy' (46.67%), 7 'Hold' (46.67%), 1 'Sell' (6.67%), and 0 'Strong Sell' (0.00%).

Fulcrum Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 13, 2024	Andrew Fein	H.C. Wainwright	$4.00	$3.44	16.28%	-8.05%
Sep 12, 2024	Gregory Renza	RBC Capital	$4.00	$3.44	16.28%	-8.05%
Sep 12, 2024	Dae Gon Ha downgraded Fulcrum Therapeutics	Stifel Nicolaus	$3.00	$3.55	-15.59%	-31.03%
Sep 12, 2024	Tazeen Ahmad	Bank of America Securities	$2.00	$3.44	-41.86%	-54.02%
Sep 09, 2024	Tazeen Ahmad	Bank of America Securities	$10.00	$8.61	16.21%	129.89%
Sep 03, 2024	Gregory Renza	RBC Capital	$15.00	$8.37	79.15%	244.83%
May 20, 2024	Kristen Kluska	Cantor Fitzgerald	$23.00	$7.55	204.64%	428.74%
May 13, 2024	Corinne Jenkins	Goldman Sachs	$15.00	$7.35	104.08%	244.83%
May 13, 2024	Dae Gon Ha	Stifel Nicolaus	$22.00	$7.48	194.12%	405.75%
Mar 13, 2024	Gregory Renza	RBC Capital	$14.00	$11.36	23.24%	221.84%
Nov 15, 2022		Goldman Sachs	$11.00	$6.81	61.53%	152.87%
Nov 08, 2022	Edward Tenthoff	Piper Sandler	$18.00	$6.37	182.80%	313.79%

The latest Fulcrum Therapeutics stock forecast, released on Sep 13, 2024 by Andrew Fein from H.C. Wainwright, set a price target of $4.00, which represents a 16.28% increase from the stock price at the time of the forecast ($3.44), and a -8.05% decrease from FULC last price ($4.35).

Fulcrum Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	10
Avg Price Target	-	-	$11.20
Last Closing Price	$4.35	$4.35	$4.35
Upside/Downside	-100.00%	-100.00%	157.47%

In the current month, the average price target of Fulcrum Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Fulcrum Therapeutics's last price of $4.35. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 13, 2024	Leerink Partners	Market Perform	Market Perform	Hold
Sep 13, 2024	H.C. Wainwright	Hold	Neutral	Downgrade
Sep 12, 2024	RBC Capital	Outperform	Sector Perform	Downgrade
Sep 12, 2024	Bank of America Securities	Neutral	Underperform	Downgrade
Sep 12, 2024	Cantor Fitzgerald	Overweight	Neutral	Downgrade
Sep 09, 2024	Bank of America Securities	Underperform	Neutral	Upgrade
Sep 03, 2024	RBC Capital	Outperform	Outperform	Hold
Jul 31, 2024	Oppenheimer	Outperform	Outperform	Hold
May 20, 2024	Cantor Fitzgerald		Overweight	Initialise
May 14, 2024	Bank of America Securities	Underperform	Underperform	Hold
Aug 23, 2023	H.C. Wainwright	Buy	Hold	Upgrade
Aug 22, 2023	Daiwa		Neutral	Downgrade
Aug 22, 2023	Compass Point		Buy	Upgrade
Aug 22, 2023	OTR Global		Mixed	Downgrade
Aug 22, 2023	Wells Fargo		Underweight	Initialise
Mar 10, 2023	Credit Suisse	Outperform	Neutral	Downgrade
Feb 28, 2023	Jefferies		Buy	Initialise
Feb 28, 2023	BMO Capital		Outperform	Initialise
Feb 28, 2023	Guggenheim		Buy	Initialise
Feb 28, 2023	Morgan Stanley	Overweight	Equal-Weight	Downgrade
Nov 15, 2022	Goldman Sachs		Buy	Initialise
Nov 14, 2022	Morgan Stanley	Overweight	Overweight	Hold
Jun 10, 2022	Piper Sandler	Overweight	Overweight	Hold
Jun 10, 2022	H.C. Wainwright	Buy	Buy	Hold
Jun 10, 2022	Oppenheimer	Outperform	Outperform	Hold
Mar 23, 2021	Credit Suisse		Outperform	Initialise

Fulcrum Therapeutics's last stock rating was published by Leerink Partners on Sep 13, 2024. The company gave FULC a "Market Perform" rating, the same as its previous rate.

Fulcrum Therapeutics Financial Forecast

Fulcrum Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20
Revenue	-	-	-	-	-	-	-	-	$871.00K	$759.00K	-	$295.00K	$685.00K	$1.18M	$1.88M	$2.59M	$5.06M	$4.93M	$4.38M	$4.79M	$4.22M	$1.85M	$750.00K
Avg Forecast	-	-	-	-	$142.86K	$112.50K	$14.82M	$416.67K	$552.72K	$1.05M	$1.12M	$1.07M	$1.89M	$2.54M	$2.96M	$3.94M	$2.68M	$2.25M	$2.40M	$2.14M	$1.31M	$687.50K	$694.44K
High Forecast	-	-	-	-	$142.86K	$112.75K	$14.82M	$416.83K	$680.27K	$1.05M	$1.12M	$1.07M	$1.89M	$2.54M	$2.96M	$3.94M	$2.68M	$2.25M	$2.40M	$2.14M	$1.31M	$687.50K	$833.33K
Low Forecast	-	-	-	-	$142.86K	$112.25K	$14.82M	$416.50K	$425.17K	$1.05M	$1.12M	$1.07M	$1.89M	$2.54M	$2.96M	$3.94M	$2.68M	$2.25M	$2.40M	$2.14M	$1.31M	$687.50K	$555.55K
# Analysts	-	-	-	-	8	4	2	2	4	2	2	2	1	1	1	1	9	9	13	9	9	15	18
Surprise %	-	-	-	-	-	-	-	-	1.58%	0.72%	-	0.28%	0.36%	0.47%	0.63%	0.66%	1.89%	2.19%	1.83%	2.24%	3.23%	2.69%	1.08%

Fulcrum Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $416.67K, with a low forecast of $416.50K, and a high forecast of $416.83K. FULC's average Quarter revenue forecast represents a -52.16% decrease compared to the company's last Quarter revenue of $871.00K (Dec 23).

Fulcrum Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20
# Analysts	-	-	-	-	8	4	2	2	4	2	2	2	1	1	1	1	9	9	13	9	9	15	18
EBITDA	-	-	-	-	-	-	-	-	$-27.48M	$-27.44M	-	$-27.94M	$-28.05M	$-22.81M	$-33.56M	$-25.46M	$-22.86M	$-20.10M	$-18.98M	$-16.40M	$-16.99M	$-18.41M	$-17.91M
Avg Forecast	-	-	-	-	$-85.71K	$-67.50K	$-8.89M	$-250.00K	$-331.63K	$-631.28K	$-669.35K	$-640.23K	$-1.13M	$-1.53M	$-1.78M	$-24.99M	$-1.61M	$-1.35M	$-1.44M	$-19.38M	$-783.92K	$-412.50K	$-16.48M
High Forecast	-	-	-	-	$-85.71K	$-67.35K	$-8.89M	$-249.90K	$-255.10K	$-631.24K	$-669.35K	$-640.23K	$-1.13M	$-1.53M	$-1.78M	$-19.99M	$-1.61M	$-1.35M	$-1.44M	$-15.50M	$-783.92K	$-412.50K	$-13.18M
Low Forecast	-	-	-	-	$-85.71K	$-67.65K	$-8.89M	$-250.10K	$-408.16K	$-631.32K	$-669.35K	$-640.23K	$-1.13M	$-1.53M	$-1.78M	$-29.99M	$-1.61M	$-1.35M	$-1.44M	$-23.25M	$-783.92K	$-412.50K	$-19.78M
Surprise %	-	-	-	-	-	-	-	-	82.88%	43.47%	-	43.64%	24.73%	14.95%	18.87%	1.02%	14.22%	14.88%	13.21%	0.85%	21.67%	44.63%	1.09%

undefined analysts predict FULC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Fulcrum Therapeutics's previous annual EBITDA (undefined) of $NaN.

Fulcrum Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20
# Analysts	-	-	-	-	8	4	2	2	4	2	2	2	1	1	1	1	9	9	13	9	9	15	18
Net Income	-	-	-	-	-	-	-	-	$-24.76M	$-24.02M	-	$-21.62M	$-23.63M	$-24.05M	$-33.91M	$-25.86M	$-23.48M	$-20.72M	$-19.65M	$-17.00M	$-17.72M	$-18.96M	$-18.45M
Avg Forecast	$-14.98M	$-15.13M	$-15.45M	$-15.76M	$-17.56M	$-24.73M	$-25.71M	$-27.30M	$-26.57M	$-27.50M	$-28.32M	$-28.90M	$-30.58M	$-38.93M	$-42.01M	$-25.52M	$-46.26M	$-41.15M	$-41.49M	$-20.09M	$-46.10M	$-41.97M	$-16.98M
High Forecast	$-14.98M	$-15.13M	$-15.45M	$-13.87M	$-14.43M	$-24.73M	$-25.71M	$-27.30M	$-23.55M	$-27.50M	$-28.32M	$-28.90M	$-30.58M	$-38.93M	$-42.01M	$-20.41M	$-46.26M	$-41.15M	$-41.49M	$-16.07M	$-46.10M	$-41.97M	$-13.58M
Low Forecast	$-14.98M	$-15.13M	$-15.45M	$-18.91M	$-21.33M	$-24.73M	$-25.71M	$-27.30M	$-30.19M	$-27.50M	$-28.32M	$-28.90M	$-30.58M	$-38.93M	$-42.01M	$-30.62M	$-46.26M	$-41.15M	$-41.49M	$-24.11M	$-46.10M	$-41.97M	$-20.37M
Surprise %	-	-	-	-	-	-	-	-	0.93%	0.87%	-	0.75%	0.77%	0.62%	0.81%	1.01%	0.51%	0.50%	0.47%	0.85%	0.38%	0.45%	1.09%

Fulcrum Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FULC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Fulcrum Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20
# Analysts	-	-	-	-	8	4	2	2	4	2	2	2	1	1	1	1	9	9	13	9	9	15	18
SG&A	-	-	-	-	-	-	-	-	$9.86M	$9.96M	-	$11.52M	$10.13M	$9.71M	$11.10M	$10.76M	$9.71M	$8.63M	$6.68M	$5.50M	$5.87M	$5.31M	$5.06M
Avg Forecast	-	-	-	-	$755.60K	$595.04K	$78.37M	$2.20M	$2.92M	$5.56M	$5.90M	$5.64M	$10.00M	$13.06M	$15.22M	$20.25M	$13.76M	$11.55M	$12.30M	$10.97M	$6.71M	$3.53M	$3.57M
High Forecast	-	-	-	-	$755.60K	$596.36K	$78.37M	$2.20M	$3.60M	$5.57M	$5.90M	$5.64M	$10.00M	$13.06M	$15.22M	$20.25M	$13.76M	$11.55M	$12.30M	$10.97M	$6.71M	$3.53M	$4.28M
Low Forecast	-	-	-	-	$755.60K	$593.72K	$78.37M	$2.20M	$2.25M	$5.56M	$5.90M	$5.64M	$10.00M	$13.06M	$15.22M	$20.25M	$13.76M	$11.55M	$12.30M	$10.97M	$6.71M	$3.53M	$2.85M
Surprise %	-	-	-	-	-	-	-	-	3.37%	1.79%	-	2.04%	1.01%	0.74%	0.73%	0.53%	0.71%	0.75%	0.54%	0.50%	0.87%	1.50%	1.42%

Fulcrum Therapeutics's average Quarter SG&A projection for Mar 24 is $2.20M, based on 2 Wall Street analysts, with a range of $2.20M to $2.20M. The forecast indicates a -77.66% fall compared to FULC last annual SG&A of $9.86M (Dec 23).

Fulcrum Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Mar 20
# Analysts	-	-	-	-	8	4	2	2	4	2	2	2	1	1	1	1	9	9	13	9	9	15	18
EPS	-	-	-	-	-	-	-	-	$-0.40	$-0.39	-	$-0.36	$-0.45	$-0.52	$-0.83	$-0.64	$-0.58	$-0.57	$-0.60	$-0.54	$-0.64	$-0.70	$-0.81
Avg Forecast	$-0.24	$-0.24	$-0.25	$-0.25	$-0.28	$-0.40	$-0.41	$-0.44	$-0.43	$-0.44	$-0.45	$-0.46	$-0.49	$-0.61	$-0.66	$-0.63	$-0.73	$-0.65	$-0.65	$-0.68	$-0.72	$-0.66	$-0.75
High Forecast	$-0.24	$-0.24	$-0.25	$-0.22	$-0.23	$-0.40	$-0.41	$-0.44	$-0.38	$-0.44	$-0.45	$-0.46	$-0.49	$-0.61	$-0.66	$-0.63	$-0.73	$-0.65	$-0.65	$-0.68	$-0.72	$-0.66	$-0.75
Low Forecast	$-0.24	$-0.24	$-0.25	$-0.30	$-0.34	$-0.40	$-0.41	$-0.44	$-0.48	$-0.44	$-0.45	$-0.46	$-0.49	$-0.61	$-0.66	$-0.63	$-0.73	$-0.65	$-0.65	$-0.68	$-0.72	$-0.66	$-0.75
Surprise %	-	-	-	-	-	-	-	-	0.94%	0.88%	-	0.78%	0.92%	0.85%	1.26%	1.02%	0.80%	0.88%	0.92%	0.79%	0.88%	1.06%	1.08%

According to undefined Wall Street analysts, Fulcrum Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FULC previous annual EPS of $NaN (undefined).

Fulcrum Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
PHAT	Phathom Pharmaceuticals	$8.37	$20.00	138.95%	Buy
RAPT	RAPT Therapeutics	$0.84	$2.00	138.10%	Hold
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
MIRM	Mirum Pharmaceuticals	$42.65	$57.00	33.65%	Buy
FULC	Fulcrum Therapeutics	$4.54	$3.25	-28.41%	Buy

FULC Forecast FAQ

Is Fulcrum Therapeutics a good buy?

Yes, according to 15 Wall Street analysts, Fulcrum Therapeutics (FULC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 46.67% of FULC's total ratings.

What is FULC's price target?

Fulcrum Therapeutics (FULC) average price target is $3.25 with a range of $2 to $4, implying a -25.29% from its last price of $4.35. The data is based on 15 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Fulcrum Therapeutics stock go up soon?

According to Wall Street analysts' prediction for FULC stock, the company can go down by -25.29% (from the last price of $4.35 to the average price target of $3.25), down by -8.05% based on the highest stock price target, and down by -54.02% based on the lowest stock price target.

Can Fulcrum Therapeutics stock reach $7?

FULC's average twelve months analyst stock price target of $3.25 does not support the claim that Fulcrum Therapeutics can reach $7 in the near future.

What are Fulcrum Therapeutics's analysts' financial forecasts?

Fulcrum Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $15.49M (high $15.49M, low $15.49M), average EBITDA is $-9.293M (high $-9.293M, low $-9.293M), average net income is $-95.31M (high $-92.173M, low $-99.074M), average SG&A $81.92M (high $81.93M, low $81.92M), and average EPS is $-1.527 (high $-1.477, low $-1.587). FULC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-61.317M (high $-59.426M, low $-64.468M), average SG&A $0 (high $0, low $0), and average EPS is $-0.982 (high $-0.952, low $-1.033).

Did the FULC's actual financial results beat the analysts' financial forecasts?

Based on Fulcrum Therapeutics's last annual report (Dec 2023), the company's revenue was $2.8M, which missed the average analysts forecast of $3.79M by -25.94%. Apple's EBITDA was $-111M, beating the average prediction of $-2.272M by 4769.74%. The company's net income was $-97.335M, missing the average estimation of $-111M by -12.54%. Apple's SG&A was $41.67M, beating the average forecast of $20.03M by 108.00%. Lastly, the company's EPS was $-1.59, missing the average prediction of $-1.783 by -10.84%. In terms of the last quarterly report (Dec 2023), Fulcrum Therapeutics's revenue was $871K, beating the average analysts' forecast of $552.72K by 57.58%. The company's EBITDA was $-27.484M, beating the average prediction of $-332K by 8187.55%. Fulcrum Therapeutics's net income was $-24.756M, missing the average estimation of $-26.568M by -6.82%. The company's SG&A was $9.86M, beating the average forecast of $2.92M by 237.41%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.426 by -6.04%